- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1472795-20-2] KRCA-0008
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-12331 |
| Brand: | MCE |
| CAS: | 1472795-20-2 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 609.12 |
| Molecular Formula | C30H37ClN8O4 |
| SMILES | ClC1=CN=C(NC2=CC=C(N3CCN(C(C)=O)CC3)C=C2OC)N=C1NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC |
1 Publications Citing Use of MCE
Summary
IC50 & Target
IC50: 12 nM (ALK), 4 nM (Ack1) [1]
In Vitro
KRCA-0008 (0-1000 μM) shows potency to ALK (wt), ALK L1196 M, ALK C1156Y, ALK F1174L, ALK R1275Q and insulin receptor with IC
50
s of 12, 75, 4, 17, 17 and 210 nM, respectively
[1]
.
KRCA-0008 (0-1000 nM; 4 h) inhibits ALK-dependent signaling pathways more potently than crizotinib
[2]
.
KRCA-0008 (0-1000 nM; 72 h) induces cell apoptosis
[2]
.
KRCA-0008 (0-100 nM; 48 h) affects cell cycle
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [1]
| Cell Line: | H3122 and H1993 cell lines |
| Concentration: | 200 nM |
| Incubation Time: | 6 hours |
| Result: | Inhibited cell proliferation of H3122 and H1993 cells with IC 50 s of 0.08 and 3.6 nM, respectively. |
Cell Proliferation Assay [2]
| Cell Line: | NPM-ALK-positive ALCL cell lines (Karpas-299 and SU-DHL-1) and U937 NPM ALK-negative lymphoma cell line |
| Concentration: | 200 nM |
| Incubation Time: | 72 hours |
| Result: | Inhibited proliferation of Karpas-299, SU-DHL-1 and U937 cells with GI 50 s of 12 nM, 3 nM and 3.5 μM, respectively. |
Western Blot Analysis [2]
| Cell Line: | Karpas-299 and SU-DHL-1 cell lines |
| Concentration: | 0, 10, 100 and 1000 nM |
| Incubation Time: | 4 hours |
| Result: | Completely suppressed phosphorylation of ALK and its effectors at a dose of 100 nM in NPM-ALK-positive ALCL cells. |
Apoptosis Analysis [2]
| Cell Line: | SU-DHL-1 cell line |
| Concentration: | 0-1 μM |
| Incubation Time: | 72 hours |
| Result: | Dose-dependently increased cspase-3/7 activities and induced cell apoptosis. |
Cell Cycle Analysis [2]
| Cell Line: | Karpas-299 and SU-DHL-1 cell lines |
| Concentration: | 0-100 nM |
| Incubation Time: | 48 hours |
| Result: | Induced G0/G1 cell cycle arrest in ALCL cells expressing NPM-ALK. |
In Vivo
KRCA-0008 (25 and 50 mg/kg; p.o. twice a day for two weeks) suppresses tumor growth in an ALK-positive Karpas-299 xenograft model [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | NOD/SCID mice with Karpas-299 xenografts [2] |
| Dosage: | 25 and 50 mg/kg |
| Administration: | Oral gavage; 25 and 50 mg/kg twice a day; for two weeks |
| Result: | Significantly inhibited tumor growth by inhibiting NPM-ALK phosphorylation without showing overt signs of toxicity or significant compound-related body weight loss. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 230 mg/mL ( 377.59 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6417 mL | 8.2086 mL | 16.4171 mL |
| 5 mM | 0.3283 mL | 1.6417 mL | 3.2834 mL |
| 10 mM | 0.1642 mL | 0.8209 mL | 1.6417 mL |
References
- [1] Park CH, et al. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Bioorg Med Chem Lett. 2013 Nov 15;23(22):6192-6.
- [2] Hwang J, et al. KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth. Invest New Drugs. 2020 Oct;38(5):1282-1291.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.